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Chapter 11
Is There a Future for mGlu5-Positive 
Allosteric Modulators in Absence Epilepsy? 
A Comparison with Ethosuximide
Gilles van Luijtelaar, Valerio D’Amore, Ines Santolini, 
and Richard T. Ngomba
Abstract Ethosuximide is the drug of choice in the treatment of various types of 
absence seizures. However, there is plenty of room for other anti-absence drugs, 
considering that not all subjects (57–74%) become seizure-free and about 47% of 
ethosuximide therapy fails. New anti-absence drugs may target or modulate gluta-
matergic and or GABAergic neurotransmission, the key players in the circuitry 
involved in the cortico-thalamo-cortical oscillations responsible for the highly ste-
reotyped spike–wave discharges (SWDs). Cortical highly excitable cells in the focal 
region form the trigger for the occurrence of SWDs.  In contrast, enhanced tonic 
inhibition is dominant in the thalamus. Biochemical studies have shown that symp-
tomatic WAG/Rij rats differ from age-matched controls in metabotropic glutamate 
(mGlu) receptor expression and function: mGlu5 receptor expression and function 
are increased in the somatosensory cortex, and mGlu1 receptor expression is 
decreased in the thalamus. The two group I mGlu receptor-positive allosteric 
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 modulators (PAMs) VU0360172 and RO0711401 have an interesting profile in 
acute and (sub)chronic pharmacological studies and produce a dose-dependent 
decrease of SWDs. Moreover, both compounds are effective in reducing SWDs in 
the cortex and thalamus. Interestingly, the GABA reuptake blocker tiagabine 
reduces SWDs in the cortex and not in the thalamus, while the efficacy of ethosuxi-
mide is higher in the cortex than in the thalamus. It is thought that VU0360172 
stimulates cortex GABA interneurons, which inhibit highly excitable cortical neu-
rons in the focal area. In the thalamus, VU0360172 most likely reduces tonic inhibi-
tion. Thus, group I mGlu receptor PAMs might be further developed as anti-absence 
drugs, with putative disease-modifying effects on epileptogenesis. The preclinical 
profile of group I mGlu receptor PAMS deserves to be further explored in models of 
generalized epilepsy and focal types of epilepsy.
Keywords VU0360172 • Positive allosteric modulator • Group I mGlu receptors • 
Absence epilepsy • Absence seizures • WAG/Rij • Genetic absence model • 
Antiepileptic drug development
11.1  Introduction
Childhood absence epilepsy (CAE) is the most common form of pediatric epilepsy, 
accounting for 10–17% of all cases. It typically begins between 4 and 8 years of age 
and is characterized by brief staring spells, often with the eyes fluttering and the 
child being unresponsive to external stimuli. Children may experience dozens to 
hundreds of these episodes per day. Ethosuximide (Etx), dating back to the 1950s, 
and valproate acid (VPA) have been for many decades and still are the drugs of first 
choice for absence seizures (Wallace 1986), while the relatively new antiepileptic 
drug lamotrigine was proposed and approved only in the mid-1990s (Frank et al. 
1999; Posner et al. 2005). It was only recently that the efficacy, safety, and tolerabil-
ity of the three compounds were compared in a large multicentered study. In 2010 a 
double-blind, randomized, comparative controlled study, including 446 patients, 
examined the efficacy and tolerability of Etx, VPA, and lamotrigine. At the week 
16–20 visit, subjects on Etx (53%) and VPA (58%) had significantly higher freedom 
from failure rates than subjects on lamotrigine. Subjects on Etx also had signifi-
cantly less attentional dysfunction compared to subjects on VPA (Glauser et  al. 
2010; Tenney and Glauser 2013). This combination of findings implied Etx as the 
optimal initial monotherapy for CAE. Despite these rather favorable outcomes and 
Etx being the “winner” at week 16–20, Etx therapy failed in 47% of subjects: 14% 
due to seizures and 24% due to intolerable side effects, while 13% withdrew from 
the study. Epidemiologic cohort studies showed only seizure freedom in the range 
from 21 to 74%. In five prospective cohort studies, the proportion of seizure-free 
subjects was 57–74%. Although labeled as a “benign” syndrome, the clinical course 
of CAE is variable, and remission rates are far lower than in other classic benign 
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idiopathic epilepsies such as benign rolandic epilepsy (Teoh and Chan 1975). 
Although a complete discussion of the adverse effects is beyond the scope of 
this review – the reader is referred to a recent review by Gören and Onat (2007) – 
the usage of Etx has been associated with commonly observed dose-dependent 
side effects related to the gastrointestinal tract, central nervous system, and 
hematopoiesis.
Most of the recent gained insights in the neurobiology of absence epilepsy were 
obtained in the genetic rodent models, in which GAERS and WAG/Rij rats were 
most commonly used. Both models mimic each other, and both are well described 
and have construct, face, and predictive validity (van Luijtelaar and Coenen 1986; 
Coenen and van Luijtelaar 2003; van Luijtelaar and Sitnikova 2006; Depaulis and 
van Luijtelaar 2006). In the last 10 years, a new dimension to the pharmacological 
treatment of absence epilepsy has been added by the proposal that Etx has, in WAG/
Rij and in GAERS besides anti-absence, also antiepileptogenic effects when treat-
ment started early and lasted 4 months (Blumenfeld et al. 2008; Sarkisova 2010; 
Russo et al. 2010; van Luijtelaar et al. 2013; Dezsi et al. 2013) and that the comor-
bidity of absence epilepsy with a mild form of depression-like behavior, typically 
for the WAG/Rij strain (Sarkisova and van Luijtelaar 2011), was prevented as a 
consequence of antiepileptogenesis by Etx (Sarkisova et al. 2010). Most relevant 
from a theoretical but also from a translational point of view is that remission has 
been found to be more than likely in high-compliance absence patients that were 
treated with Etx (Berg et al. 2014). It can be concluded that Etx is the most precious 
tool in the treatment of absence epilepsy and that it is certainly not without prob-
lems, including the relative high failure rate, and its putative adverse effects suggest 
that there must be room for new and better anti-absence drugs. Since Etx is the drug 
of choice, new and better anti-absence drugs must be compared with Etx.
11.2  The Assumed Working Mechanisms of ETX
It has long been thought that the action of Etx is to block It currents in thalamic- 
cortical (TC) relay cells and, consequently, the burst firing mode of these cells. The 
burst firing of TC cells was assumed to be the neurophysiological substrate of SWD 
activity in cortico-thalamo-cortical pathways. These ideas were developed in the 
beginning of 1990s based on in vitro neurophysiologic studies using voltage-clamp 
techniques in acutely isolated neurons of the ventrobasal complex of the thalamus 
from rats and guinea pigs. Therapeutically relevant concentrations of Etx induced a 
reduction of the low-threshold Ca2+ current, which was most pronounced at more 
hyperpolarized potentials first in the thalamic relay nuclei with no change in its 
kinetics or steady-state properties (Coulter et al. 1989; Macdonald and Kelly 1993; 
White 1999); the later was also found for neurons in the reticular thalamic nucleus 
(RTN) (Huguenard and Prince 1994). It was generally felt that virtually all thalamic 
neurons are endowed with a prominent low-threshold Ca2+ conductance that is of 
sufficient magnitude to generate a low-threshold Ca2+ spike (LTS) with its 
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accompanying burst firing mode of thalamic cells (Jahnsen and Llinás 1984a, b; 
Deschênes et al. 1984). Later, it was established that this conductance is crucial for 
the generation of normal thalamo-cortical oscillations such as sleep spindles 
(Steriade and Llinás 1988) and for the occurrence of delta waves, typical of deep 
slow sleep (Domich et al. 1986; Crunelli et al. 2014). The possibility was raised that 
this conductance may also play a key role in the development of pathological SWDs, 
and this idea was thought to be a sufficient explanation for the working mechanism 
of Etx in reducing SWDs in absence epilepsy patients.
However, Etx also decreases persistent Na+- and Ca2+-activated K+ currents in 
thalamic and layer V cortical pyramidal neurons (Leresche et al. 1998; Crunelli and 
Leresche 2002a), which may also explain the decrease in burst and increase in tonic 
firing. This newly discovered mechanism of Etx casts doubts on the hypothesis that 
only a reduction of IT in thalamic neurons underlies the therapeutic action of this 
anti-absence medicine (Crunelli and Leresche 2002b). In addition, there is evidence 
in a genetic absence epilepsy rat model that Etx reduces cortical γ-aminobutyric 
acid (GABA) levels (Greenhill et al. 2012). Also, elevated glutamate levels in the 
primary motor cortex of rats with absence epilepsy (but not in normal animals) are 
reduced by Etx. In addition, whole-cell patch-clamp studies revealed an increase in 
spontaneous GABA release by Etx concurrent with no change in glutamate release 
at synapses in the rat’s entorhinal cortex in vitro (Greenhill et al. 2012). This was 
reflected in a substantial rise in the ratio of network inhibition to excitation and a 
concurrent decrease in excitability of neurons embedded in this network. These 
authors concluded that Etx directly elevates synaptic inhibition in the cortex next to 
its well-established effects on ion channels and that both factors contribute to the 
well-known anti-absence effects. Interestingly, an increase in synaptic inhibition of 
cortical cells was also found after tiagabine administration by the same authors.
The notion that Etx facilitates cortical inhibition is relevant considering that 
there is now good evidence that generalized absence seizures in the genetic models, 
but also in a model in which systemic administration of low-dose PTZ induces 
absence-like seizures, are initiated at a cortical focus in the deep layers of the peri-
oral region of the somatosensory cortex (Meeren et al. 2002; Polack et al. 2007). 
Subsequent studies revealed that Etx exerted an immediate and strong anti-absence 
action when injected in the somatosensory cortex but not the cortex in general 
(Manning et al. 2004; Polack and Charpier 2009). Moreover, in vivo studies showed 
that the majority (60%) of cat TC neurons are completely silent during SWDs 
(Steriade and Contreras 1995), and in GAERS, no LTSs were recorded in TC neu-
rons during the majority (90%) of SWDs (Pinault et al. 1998; Slaght et al. 2002). 
However, hyperpolarized mediated LTSs and the burst firing mode were seen in 
RTN during SWDs in GAERS (Slaght et al. 2002), and indeed microinfusion of Etx 
into the ventral basal complex of the thalamus produced only a weak and delayed 
anti-absence effect, while the effects in the RTN were of a larger magnitude. In all, 
the outcomes of these studies question the notion that Etx exerts its therapeutic 
effect to a large extent on the relay nuclei of the thalamus (Manning et al. 2004) and 
only by blocking IT channels.
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Hypotheses on the working mechanisms of Etx can also be inferred from drug 
interaction studies. Moreover, drug interaction studies are clinically relevant con-
sidering that monotherapy often fails, and seizure control can be only achieved with 
polytherapy. In order to evaluate the combination of Etx with other anti-absence 
drugs, the single and combined effects of VPA acid and Etx have been studied. The 
incidence of SWDs was the readout variable. The median effective doses (ED50 
values) in this model were 121 and 21.5 mg/kg for VPA and Etx, respectively (van 
Rijn et al. 2004). When the agents were administered together, the interaction was 
shown to be infra-additive: the combination was less effective in diminishing the 
incidence of SWDs in WAG/Rij rats than could be anticipated and based on the net 
effect of the drugs administered alone. This is considered as indirect evidence that 
the two anti-absence drugs share some common cellular or molecular mechanism, 
perhaps blocking Na+ channels or increasing GABA levels in the cortex.
11.3  New Anti-absence Drugs
The search for new anti-absence drugs has been concentrated on drugs that target 
the circuitry in which the absence epilepsy characteristic SWDs are elicited, main-
tained, and aborted. For typical absence epilepsy, it is undoubtedly the reciprocally 
interconnected cortico-thalamo-cortical network including the RTN (van Luijtelaar 
and Sitnikova 2006; Blumenfeld 2005; Lüttjohann and van Luijtelaar 2015; Stefan 
and Lopes da Silva 2013); for atypical absence epilepsy, it is more likely a hippo-
campal, thalamo-cortical circuit (Onat et al. 2013). GABA and glutamate are the 
major neurotransmitter systems within the interconnected cortex and thalamus. 
Therefore, it seems logical to investigate the role of these neurotransmitter systems 
on the incidence of SWDs. In the mid-1990s, drugs affecting ionotropic glutamate 
receptors were in the focus of interest, and as was expected, all subclasses of 
antagonists reduced SWDs, while agonists enhanced SWDs in the WAG/Rij 
absence model (Peeters et al. 1990; Ramakers et al. 1991; Jakus et al. 2004; van 
Luijtelaar and Zobeiri 2014). However, many of the ionotropic receptor antagonist 
compounds had toxic effects, and despite their anti-absence and anticonvulsant 
action, most of the ionotropic glutamate antagonists were not further developed as 
antiepileptic drugs.
Since targeting mGluRs might be less toxic than targeting ionotropic glutamate 
receptors, we decided to focus on the role of mGluRs, also considering that drugs 
targeting mGluR have been shown to exert pro- or antiepileptic effects in various 
seizure and epilepsy models (Alexander and Godwin 2006). More specifically, 
orthosteric antagonists of group I mGluRs reduced motor seizures induced by sound 
stimulation in DBA mice as well as nonconvulsive (absence) seizures in the lethar-
gic mice (Chapman et al. 1999, 2000) – the latter is a genetic absence model with 
ataxia and hypoactivity – while the nonselective orthosteric agonist DHPG targeting 
both type 1 and 5 receptors enhanced convulsions elicited by audiogenic stimulation 
in DBA mice (Moldrich et al. 2003). The role of orthosteric agonists on  nonconvulsive 
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epilepsy has not been investigated. Interestingly, besides orthosteric agonists and 
antagonists, also selective positive and negative allosteric modulators (PAMs and 
NAMs) are currently developed and available. These PAMS and NAMS might be 
even more subtle in inducing changes. A second reason was that mGluRs are widely 
distributed in the cortico-thalamo-cortical networks (Ngomba et  al. 2011a), the 
brain circuitry in which SWDs originate, are maintained, and end (Cheong et al. 
2009; Lüttjohann and van Luijtelaar 2015). These networks consist of a large num-
ber of subtypes of mGluRs, and they are selectively present in different parts of the 
circuitry, offering possibilities for selective targeting of disease-modified (sub)sys-
tems. Here we focus specifically on the role of group I mGluRs, with their two 
subtypes (1 and 5), in the pathogenesis of absence epilepsy and whether drugs 
affecting this system might be used for anti-absence therapy. It is known that group 
I mGluRs are involved in absence epilepsy because knockdown as well as whole- 
animal knockout of PLCβ4, a protein involved in the group I signaling pathway, 
induced spontaneous SWDs in mice with simultaneous behavioral arrest. In addi-
tion, the susceptibility to drug-induced SWDs was increased in these knockout 
mice, indicating that the deletion of thalamic PLCβ4 leads to the genesis of absence 
seizures (Cheong et al. 2009). Interestingly, PLCβ4 colocalizes with mGlu1 recep-
tors and mediates mGlu1 receptor signaling in thalamic nuclei (Miyata et al. 2003; 
Watanabe et al. 1998). Also, the pharmacological studies of Chapman et al. (1999, 
2000; Moldrich et al. 2003) on the lethargic mice absence model suggest a role of 
group I receptors in nonconvulsive seizures mediated in thalamo-cortical 
networks.
11.4  Neurochemical Studies
As mentioned above, mGluRs are widely distributed in the cortico-thalamo-cortical 
networks (Ngomba et al. 2011a). In the thalamus, group I mGluRs are located on 
relay neurons in the ventrobasal thalamus postsynaptic to the cortical inputs 
(Ferraguti et al. 2008; Romano et al. 1995; Liu et al. 1998). Moderate-to-low mGlu5 
receptor mRNA and protein levels are expressed in RTN neurons (Romano et al. 
1995; Lourenço Neto et al. 2000), whereas these neurons do not express mGlu1R 
mRNA (Shigemoto et al. 1992). MGlu1Rs in the cortex are located postsynaptically 
on GABAergic interneurons (Stinehelfer et al. 2000), and mGlu5Rs are expressed 
by pyramidal neurons postsynaptic to thalamo-cortical projections (Wijetunge et al. 
2008), as well as by interneurons (Romano et al. 1995; Sun et al. 2009). Group I 
mGluRs are coupled to Gq/G11 proteins, and their activation stimulates polyphos-
phoinositide hydrolysis with formation of inositol-1,4,5-trisphosphate and diacylg-
lycerol and also regulates the activity of different types of Ca2+ and K+ channels 
(Nicoletti et al. 2011).
Several studies on expression and function were performed in the WAG/Rij 
model in order to assess the role of mGluRs in the pathophysiology of nonconvul-
sive epilepsy. In the WAG/Rij rat absence model, the SWDs start to become present 
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in the cortical EEG from 2 to 3 months of age and onward. The analysis of expres-
sion of mGluRs was carried out by using symptomatic WAG/Rij rats (minimally 6 
months of age) and presymptomatic WAG/Rij rats (not more than 2 months of age) 
which were compared with age-matched control non-epileptic ACI rats. Various 
parts of the cortico-thalamo-cortical network, such as RTN, ventrobasal thalamic 
nuclei, somatosensory cortex, and motor cortex, were inspected (Ngomba et  al. 
2011b; D’Amore et al. 2013). The functional activity of group I mGluRs was exam-
ined by using an in vivo method that allowed measurements of agonist-stimulated 
PI hydrolysis after incorporation of [3H]inositol into the phospholipids of living 
rats (Molinaro et al. 2009). mGlu1 or mGlu5 receptor function was evaluated in the 
thalamus and in the somatosensory cortex and compared to age-matched controls.
Both the expression and function of mGlu1 and mGlu5 receptors were reduced 
in the thalamus of symptomatic WAG/Rij rats compared to age-matched non- 
epileptic ACI rats. Lower levels of group I subtype protein receptors in the thalamus 
of the symptomatic WAG/Rij rats were confirmed by immunohistochemical analy-
sis (Ngomba et al. 2011b). Moreover, these data showed that the reduced expression 
of mGlu1α receptors found in symptomatic WAG/Rij rats was observed in the 
dorsal and medial nuclei, but not in the ventroposterolateral thalamus. Furthermore, 
no mGlu1α receptor mRNA was observed in the RTN, and no change in mGlu1α 
receptor signaling was detected in the somatosensory cortex of symptomatic WAG/
Rij rats compared to age-matched control ACI rats. The level of mGlu1α receptors 
in the thalamus and the developmental changes in expression in different thalamic 
nuclei were also investigated by Karimzadeh et al. (2016) in presymptomatic and 
symptomatic WAG/Rij rats and compared with age-matched non-epileptic wistar 
controls. These authors found that the protein level of mGlu1α receptors in the 
thalamus of the symptomatic WAG/Rij rats was lower than in non-epileptic animals. 
In addition, the number of mGlu1α receptors in different thalamic nuclei was lower 
in the 6-month-old WAG/Rij compared to age-matched wistar control rats. The gene 
expression of mGlu1α receptor was also significantly lower in 6-month-old WAG/
Rij rats in the lateral dorsal part of the thalamus compared to all other groups. In 
contrast, the expression of mGlu5Rs was increased either in the somatosensory or 
motor cortex of symptomatic WAG/Rij rats, as assessed by immunohistochemical 
and Western blot analysis (D’Amore et al. 2013). In all, these neurochemical data 
demonstrate that absence epilepsy in this genetic model is accompanied by signifi-
cant changes in expression and function of group I mGluR in relevant parts of the 
SWD-generating circuit.
11.5  Acute and Subchronic Pharmacological Studies
Considering our aim to evaluate putative new treatments for absence epilepsy, the 
effects of selected group I and subgroup 1 PAMs on the occurrence of spontaneous 
absence seizures were first investigated (Ngomba et al. 2011b). Adult symptomatic 
rats of the WAG/Rij strain were treated systemically with RO0711401 (3, 10, or 30 
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mg/kg, s.c.), a selective PAM at mGlu1Rs (Vieira et  al. 2009). The outcomes 
indicated that 3 mg/kg of RO0711401 could only abolish the early stress-related 
increase in the incidence of SWDs; 10 mg/kg was required for a substantial reduc-
tion in the incidence of SWDs; and 30 mg/kg could reduce the incidence as well as 
the mean duration of trains of SWDs. To further demonstrate a protective role for 
mGlu1Rs against SWDs, the same rats were systemically injected with JNJ16259685 
(2.5 or 5  mg/kg, i.p.), a selective NAM of mGlu1 receptors. Treatment with 
JNJ16259685 increased the incidence of SWDs in a dose-dependent manner 
(Ngomba et al. 2011b). In fentanyl-anesthetized WAG/Rij rats, a microinjection of 
the selective mGlu1α receptor agonist DHPG in the lateral dorsal thalamus reduced 
the mean duration of SWDs, and the selective antagonist LY367385 increased the 
amplitude of the spikes of the SWDs and the mean duration of SWDs in symptom-
atic WAG/Rij rats. These results were in line with the results obtained in the free-
moving WAG/Rij rats (Karimzadeh et al. 2016).
Group I (mGluR1 and mGluR5) receptors show a different pattern of distribution 
in the C-T-C network, which suggests distinct rather than complementary functions 
of these two receptor subtypes. Therefore, our pharmacological investigation was 
extended to mGlu5 receptors. The pharmacological enhancement of mGluR5 activ-
ity with the PAM VU0360172 at doses of 3 and 10 mg/kg, s.c., known to be cen-
trally active (Rodriguez et al. 2010), caused a robust and dose-dependent reduction 
in the incidence and mean duration of SWDs. The acute treatment with MTEP (10 
or 30  mg/kg, i.p.), a selective NAM of mGlu5 receptors (Anderson et  al. 2002; 
Cosford et al. 2003), did not change the incidence and mean duration of the SWDs 
(D’Amore et al. 2013).
From a therapeutic standpoint, it is important to establish whether tolerance is 
developed to the action of these putative anti-absence drugs. Effective doses of 
VU0360172 (3 mg/kg, s.c.) and RO0711401 (10 mg/kg, s.c.) were administered to 
rats twice daily for 10 days, and incidence of SWDs was determined across this 
period (D’Amore et  al. 2014, 2013). As expected (Ngomba et  al. 2011b), both 
mGlu1 and mGlu5 receptor PAMs suppressed the incidence of SWDs in the first 2 
days of treatment. The anti-absence effect of the mGlu5 receptor PAM (VU0360172) 
persisted largely over the 10-day administration period with only a small sign of 
tolerance. In contrast, rats quickly developed complete tolerance to RO0711401 
from the third day of treatment. Next, it was wondered whether chronic treatment 
with RO0711401 or VU0360172 would cause desensitization of mGlu1 and 
mGlu5Rs in symptomatic WAG/Rij rats and in non-epileptic age-matched wistar 
control rats (D’Amore et al. 2014). Chronic administration of VU0360172 increased 
the expression of mGlu5 receptors in the thalamus and in the cortex of WAG/Rij rats 
without changing the expression of mGlu1α receptors. Treatment with RO0711401 
enhanced the expression of both mGlu1α and mGlu5 receptors in the thalamus and 
cortex of WAG/Rij rats. Opposite data were obtained in non-epileptic wistar rats, 
in which repeated injections of the two PAMs downregulated the expression of 
mGlu1α and mGlu5Rs. RO0711401 changed the expression of both the mGlu1α 
and the mGlu5Rs in WAG/Rij and wistar rats, whereas VU0360172 selectively 
changed the expression of mGlu5Rs only (D’Amore et al. 2014). These pharmacody-
G. van Luijtelaar et al.
215
namic and accompanying pharmacokinetic studies could not explain the large 
differences between VU0360172 and RO0711401  in terms of tolerance to the 
SWD-suppressing effects.
All these outcomes contribute to highlight the key role of group I mGluRs in the 
pathophysiology of absence seizures, at least in the spontaneous absence seizure 
model rats of the WAG/Rij strain. Moreover, they suggest that chronic administra-
tion of group I PAMS may change the expression of mGlu1a and mGlu5Rs in the 
cortex and thalamus, that these changes might be different for the two different 
PAMS, and that the genetic context (WAG/Rij vs lethargic mice) may also be cru-
cial for the changes in receptor function after repeated administration.
11.6  Local Injection Studies
The next step was a C-T-C circuit demarcation strategy adopted by independent 
intracortex or intra-thalamus (ventral basal complex) microinfusions to investigate 
site-specific effects on the regulation of SWDs. WAG/Rij rats received bilateral 
microinfusion of RO0711401 or VU030172. The two drugs were equally effective 
in reducing the incidence of SWDs when injected into the cortex. Both drugs were 
also effective in reducing SWD incidence when they were infused in the thalamus, 
although the mGlu5 PAM VU036012 displayed somewhat greater thalamic efficacy 
than the mGlu1 PAM RO0711401 (D’Amore et al. 2015).
Dysfunction of glutamatergic or GABAergic neurotransmission is supposed to 
be a cause of the initiation and spread of seizures. Moreover, glutamate and GABA 
interact at many locations within the C-T-C network. Therefore, the effects of 
tiagabine – a GABA reuptake inhibitor at the neuronal or glial GAT-1 transporter – 
locally administered to the cortex and thalamus was investigated. Cortical adminis-
tration of tiagabine resulted in a dose-dependent decrease in the incidence of SWDs, 
an effect similar to the effects of the group I PAMs. In contrast, intra-thalamic injec-
tions of tiagabine showed a dose-dependent increase in the incidence of SWDs, an 
effect opposite to that obtained with the PAMs.
Next, the interaction between GABA and glutamate was investigated. More pre-
cisely, it was established whether and in which direction an increased availability of 
(extra)synaptic GABA influences responses to VU0360172 in the thalamus and cor-
tex. Combined microinjections of VU0360172 and tiagabine were carried out. 
Co-administration of VU0360172 and tiagabine reduced the incidence of SWDs 
when injected in the cortex, an effect similar to the effects of both compounds alone. 
Moreover, an indication was obtained for subadditive effects of the two drugs. In 
contrast, completely opposite effects were observed after co-administration to the 
thalamus: a decrease followed by an increase in the incidence of SWDs was seen, 
suggesting that the effects of VU0360172 were completely blocked in the presence 
of increased GABA (D’Amore et al. 2015).
In all the above mentioned pharmacological experiments with PAMs and NAMs, 
the behavior of the rats was quantified with the aid of a calibrated infrared  movement 
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detector; it allowed the quantification of the amount of activity during the EEG 
recording session. In none of the experiments described above did VU0360172 
affect the behavior of the rats.
It can be concluded that these pharmacological studies demonstrate dose- 
dependent SWD decreasing effects of both PAMs, minimal tolerance in a twice 
daily 10-day administration protocol of VU0360172, and the quick development of 
tolerance to RO0711401. Local injections of both PAMs demonstrated that the com-
pounds are effective in reducing SWDs in the cortex and thalamus. Effects on 
behavior were not noticed. In all, VU0360172 has a good preclinical profile as an 
anti-absence drug in the WAG/Rij absence model.
11.7  Comparison Between Ethosuximide and VU0360172
The preclinical profile of VU0360172 as an anti-absence drug, as described here, 
seems promising, but this specific PAM has not been tested yet in other assays and 
models. Etx has a 60-year-long tradition, and much is known regarding its clinical 
efficacy and adverse effects. Etx has the best clinical profile among available anti- 
absence drugs, and new anti-absence drugs have to be compared with it. Recent 
reviews also point toward the limitations of Etx. These limitations clearly demon-
strate the need for other treatment options. Many earlier in vivo and in vitro neuro-
physiologic studies on healthy animals, such as rats, cats, and ferrets, with 
pharmacologically induced seizures (e.g. Coulter et  al. 1989, Huguenard and 
Prince 1994; Deschênes et al. 1984; von Krosigk et al 1993; Porcello et al. 2003) 
have found that Etx acts in the thalamus and by blocking Ca2+ channels, both in the 
relay nuclei and in the RTN. The comparative cortex-thalamus local injection stud-
ies of Manning et al. (2004) in the GAERS model and the outcomes of the neuro-
physiologic studies of the Pinault and Crunelli groups (Leresche et  al. 1998; 
Crunelli and Leresche 2002b; Pinault et al. 1998) have yielded a somewhat differ-
ent focus, regarding the location where Etx exerts its anti-absence effect, the 
assumed role of thalamic bursting neurons during SWDs, and the mechanisms of 
action. Relevant in this context is that these authors did most of their experiments 
in vivo in the well- characterized GAERS model and not on slices from healthy 
animals. Etx exerts its action predominantly in the cortical focal area in the somato-
sensory cortex, not in other cortical regions in the GAERS model. The action of 
Etx was also demonstrated in the thalamic ventral basal complex and RTN 
(Manning et al. 2004; Richards et al. 2003), although its efficacy in the thalamus 
was clearly less (Fig. 11.1).
The comparison of the local (cortical and thalamic) effects of both drugs is pre-
sented in Fig. 11.1. Both Etx and VU0360172 show a good SWD-suppressing effect 
in the cortex; however, the SWD-suppressing effects of VU0360172 in the thalamus 
seem to be more pronounced than those of Etx, although it is risky to compare 
results of different studies.
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Our results show that VU0360172 acts well in two target areas, while this seems 
less to be the case for Etx. VU0360172 and RO0711401 were equally effective in 
the somatosensory cortex and ventral basal part of the thalamus. This strongly sug-
gests that both PAMs may target both locations equally and effectively and that this 
may contribute to successful seizure suppression of both group I PAMs.
11.8  Discussion
There is plenty of evidence that group I mGluR PAMs aggravate glutamatergic neu-
rotransmission: binding of these PAMs increases the affinity of glutamate-site ago-
nists at its extracellular N-terminal binding site, group I PAMs potentiate synaptically 
evoked mGlu1 receptor responses in rat brain slices (Knoflach et  al. 2001), and 
mGlu1R stimulation enhances excitability in layer V cortical neurons without any 
effect on GABAergic neurotransmission (Bandrowski et  al. 2003). Therefore, at 
first glance, the SWD-reducing effects of the PAMs VU0360172 and RO0711401 
seem puzzling considering that the glutamatergic ionotropic receptor agonists 
aggravate SWDs in the genetic rodent models (Peeters et al. 1990; Ramakers et al. 
Fig. 11.1 Representative figure: Incidence of SWDs 30 min after bilateral microinfusion of artifi-
cial cerebrospinal fluid (ACSF), Ethosuximide (ETX), or VU3601726 in the thalamus and cortex 
(After Manning et al. 2004; D’Amore et al. 2015)
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1991; Jakus et al. 2004; van Luijtelaar and Zobeiri 2014). However, the outcomes of 
our local injection study might give two clues why this PAM reduces SWDs. The 
first regard the outcomes of cortical injections of the PAM alone, tiagabine alone, 
and the combination of both drugs. The PAM VU0360172 had, when injected in the 
focal area, the same action as tiagabine, a drug known to block GABAergic reup-
take. The combined administration showed subadditive effects, suggesting that both 
drugs targeted the same mechanism. We proposed that VU0360172 and RO0711401, 
its receptors being present postsynaptically on GABAergic interneurons, stimulate 
the activity of GABAergic interneurons, facilitating the release of GABA and 
diminishing SWDs. This would fit nicely with the view that SWDs in the rodent 
models are due to enhanced local cortical excitation and reduced local inhibition 
(van Luijtelaar and Sitnikova 2006; Lüttjohann et al. 2011). Whether this mecha-
nism of VU0360172 is only valid for the cortex of genetic epileptic rats, with their 
epilepsy-related changes in cortical mGlu5 receptor expression and function, as 
mentioned in the section on biochemistry, needs to be established. The second clue 
comes from the thalamic injection studies. Group I PAMs infused in the thalamus 
suppress SWDs. Here it is thought that they reduce the assumed increased tonic 
inhibition (Cope et al. 2009), a second reason for SWDs to occur in the genetic rat 
models. Also, our data on local infusion of tiagabine, showing a dose-dependent 
increase in SWDs, are in full agreement with the tonic inhibition hypothesis  of 
Cope and colaborators.
From a drug development perspective, it is important to mention that none of the 
local injection studies were effects on the motor system of the rats observed, 
 suggesting that the motor system does not seem to be largely affected by group I 
PAMs. This is in clear contrast to the large effects of some of the ionotropic gluta-
matergic agonists, such as MK801. The lack of behavioral effects in our EEG study 
suggests that the anti-absence effects of the PAMs are not secondary to changes in 
behavior or sleep–wake behavior, as far as this could be inferred from our quantita-
tive behavioral measurements. Interestingly, VU0360172 did not affect spontane-
ous locomotor activity in an open field, but it did dose-dependently reduce 
hyperlocomotion induced by amphetamine (Rodriguez et  al. 2010). Tolerance 
toward the anti-absence action of a twice daily 10-day drug administration regimen 
was minimal with VU0360172 in contrast to RO0711401. With the latter drug, tol-
erance was absent in the first 2 days, but on the third day (after five injections), it 
was complete. Neurotoxic studies with higher doses of VU0360172, such as the 
measurement of a motor coordination in a rotor-rod task, measures on sedation, and 
analgesia of higher doses of the drug, are indicated. To establish whether the com-
pound affects cognition is challenging. Fortunately, group I PAMs have already 
been proposed for the treatment of psychosis and cognitive disturbances in schizo-
phrenic patients, since they enhance certain forms of neural plasticity via LTD and 
LTD, learning, and memory processes (Rush et al. 2002). The latter properties were 
ascribed to the ability of PAMs to indirectly potentiate the function of NMDA 
receptors; our cortical injection studies suggest that the action of group I PAMs 
might, in addition to this well-known effect, facilitate cortical GABAergic trans-
mission. The drug deserves and needs to be investigated for its putative antiepileptic 
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action in other models of seizure and epilepsy. This is also indicated considering the 
interaction between VU0360172 and tiagabine, as found in the thalamus. The bal-
ance between glutamate and GABA is disturbed in many types of epilepsy, includ-
ing mesial temporal lobe epilepsy. Also in these models, group I PAMs may increase 
the diminished GABAergic inhibition. In vivo imaging of mGluR5 via microPET/
CT revealed regional changes of mGluR5-binding potential of the rat brain in a 
pilocarpine- induced epilepsy model. The temporal and spatial changes in mGluR5 
availability suggest an abnormal glutamatergic network during epileptogenesis 
(Choi et al. 2014).
Antiepileptic drugs are often given in combination, considering that monother-
apy might often be insufficient for full seizure control. However, many antiepileptic 
drugs are enzyme inducing and lower the efficacy of other medications. Etx showed 
an infra-additive effect with VPA (van Rijn et al. 2004); drug combination studies 
with group I PAMs are necessary. A first drug interaction study on VU0360172 with 
chronically administered Etx showed that it kept its anti-absence action but without 
time and dose dependency (D’Amore et al. 2016). The data also suggested that the 
PAM can be used as an adjunct therapy in patients with absence epilepsy, as well as 
being used in monotherapy. Whether our group I PAM has disease-modifying prop-
erties that stop epileptogenesis is also important. Beneficial effects on cell prolifera-
tion by a mGluR1α agonist after episodes of early-life status epilepticus were 
recently described (Friedman et  al. 2016). It might be relevant to investigate the 
disease-modifying properties of group I PAMs in other models as well.
It needs to be added that the results obtained on the direction of the effects of 
group I PAMs and NAMs on absence epilepsy as described here (PAMs reduce, 
NAMs enhance, or have no effect) are opposite to what has been described in 
another genetic model: the lethargic mice. A discussion on the validity of the 
GAERS and WAG/Rij models vs the lethargic mouse model is out of the scope of 
this paper; it is well known that the latter has a complex phenotype (besides 
absences seizures, it presents with chronic ataxia, hypoactivity, and transient 
attacks of severe dyskinetic motor behavior) next to a large GAD(67) expression in 
thalamic cells and disturbances in the GABAB receptor system accompanied by an 
involvement of T-type voltage-gated Ca2+ channels. It is obvious, though, that dif-
ferences in the direction of the effects of the mGlu modulators in the two genetic 
absence models could be due to the genotype and to different causes of the absence 
seizures. Another possibility is that the PAMs and NAMs act differently in the two 
species because of changes in group I receptor expression and function in absence 
epilepsy-relevant parts of the brain. In order to solve the issue regarding the oppo-
site direction of the effects in the two models, the same compounds should be 
investigated in the two models.
Although the used PAM is considered selective for mGlu5R, VU0360172 does 
not interact in a fully competitive manner with the prototypic allosteric binding site, 
in contrast to some other recently synthetized mGlu5 PAMs (Rook et  al. 2015). 
Whether this property contributes to its anti-absence action in vivo remains to be 
established. If so, this would offer unique chances for discovering new mechanisms 
of absence seizures.
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